MOTS-c

Mechanism of action

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid endogenous peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene — the first mitochondrial-derived peptide (MDP) discovered with established metabolic-regulatory function, identified by Pinchas Cohen and colleagues at the University of Southern California (Lee et al., Cell Metab 2015). Unlike most peptides encoded by the nuclear genome, MOTS-c is one of a small number of bioactive peptides whose primary genetic instructions reside in the mitochondrial genome — a discovery that has broader implications for understanding the mitochondrial-nuclear retrograde signalling that coordinates cellular energy status with broader physiology. MOTS-c is translated within mitochondria, released to the cytoplasm, and either retained in the cytoplasm or exported to circulation. Its plasma concentration declines with age and is reduced in subjects with type-2 diabetes — observations that initially supported the hypothesis of MOTS-c as an endogenous regulator of metabolic homeostasis that declines with the aging-and-metabolic-disease phenotype. The principal mechanistic action of MOTS-c is activation of AMP-activated protein kinase (AMPK) signalling. AMPK is the central cellular energy-sensor, activated by elevated AMP:ATP ratios (energy depletion) and by upstream kinases (LKB1 in the canonical pathway, CaMKK2 in calcium-dependent activation). MOTS-c activation of AMPK appears to proceed at least partly through modulation of the folate cycle: MOTS-c competes with methotrexate at folate-cycle enzymes, alters intracellular AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) accumulation, and through the AICAR mechanism activates AMPK. The folate-cycle component connects MOTS-c mechanistically to broader one-carbon metabolism, which has received increasing attention as a regulator of insulin sensitivity, mitochondrial function, and longevity. Downstream of AMPK activation, MOTS-c produces multiple cellular effects: enhanced fatty acid oxidation in skeletal muscle, improved glucose uptake through GLUT4 translocation (insulin-independent), suppressed lipogenesis through inhibition of ACC, increased mitochondrial biogenesis through PGC-1α activation, and modulation of the mTOR-autophagy balance toward autophagic flux. In aged mice, MOTS-c administration reverses age-related insulin resistance, improves exercise capacity (treadmill running endurance), and increases physical activity — effects that parallel some of the metabolic phenotypes observed in caloric restriction and AMPK-activating interventions like metformin. More recent mechanistic work has identified MOTS-c effects on bone metabolism (anti-osteoporotic effects in ovariectomised mice), cardiac function (cardioprotective effects in heart failure models), and immune regulation (modulation of T-cell function). The broad pleiotropy reflects the upstream position of AMPK in cellular energy signalling — many tissues respond to AMPK activation with tissue-specific effects relevant to research. A distinguishing pharmacological feature of MOTS-c versus other metabolic peptides is its action on the AMPK pathway rather than the incretin pathway. This places MOTS-c mechanistically alongside metformin and exercise-mimetic compounds rather than alongside semaglutide and tirzepatide. The two pathways are pharmacologically complementary — incretin pharmacology drives glucose-dependent insulin secretion and central appetite suppression; AMPK pathway pharmacology drives insulin-independent glucose disposal and peripheral metabolic homeostasis. Combined modulation has plausible mechanistic rationale but has not been clinically characterised.

MOTS-c administration to aged mice restores exercise capacity (treadmill endurance), increases physical activity, and reverses age-related insulin resistance and metabolic decline (Reynolds et al., Nat Commun 2021) — establishing the first pharmacological demonstration that supplementation of an age-declining mitochondrial-derived peptide can restore a functional phenotype of youth in mammals.

— Notable finding

Research history

MOTS-c was discovered and characterised by the laboratory of Pinchas Cohen at the University of Southern California (formerly UCLA), with the seminal publication in Cell Metabolism in 2015 (Lee et al.) identifying the 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region and establishing its metabolic-regulatory function in skeletal muscle and adipose tissue. The discovery extended the mitochondrial-derived peptide (MDP) field that had begun with humanin in 2003 (Tajima et al.) and subsequently expanded to include SHLP1-6 and other smaller MDPs. Follow-on academic work across 2015-2024 has characterised MOTS-c pharmacology across multiple research applications: type-2 diabetes models, exercise and athletic performance research, age-related metabolic decline, bone metabolism, cardiac function, and emerging immune-modulation work. The pre-clinical evidence base has grown substantially, with hundreds of publications across the broader MDP field and dozens specifically on MOTS-c. Clinical development of MOTS-c has been more limited. Early-phase exploratory clinical work has been initiated at academic centres but has not progressed to full Phase II/III commercial development. CohBar Inc, a publicly-traded biotech founded by Pinchas Cohen and others to develop MDP-based therapeutics, advanced several MDP-related compounds (though not MOTS-c specifically as the lead) through Phase I but did not progress to registration. The company's development trajectory and broader MDP commercialisation has been complicated by the off-patent nature of the endogenous peptide sequences and the methodological challenges of mitochondrial-derived peptide drug development. MOTS-c entered the research-chemical market in the late 2010s and has gained moderate visibility in research-chemical-community contexts, particularly in the longevity and metabolic research overlap. The compound is grouped with other metabolic peptides (semaglutide, tirzepatide, AOD-9604) and with longevity peptides (epitalon, humanin) depending on the framing of any given research-community discussion. Research-chemical supply is widely available at moderate cost. As of 2026, MOTS-c is not licensed in any jurisdiction. No active commercial Phase III development programme is known. The compound exists in academic research and research-chemical channels.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

MOTS-c safety data come primarily from pre-clinical work and limited early-phase exploratory clinical studies. The pre-clinical safety record across rodent metabolic and exercise studies has been favourable: subcutaneous doses of 0.1-15 mg/kg over weeks-to-months have produced no overt toxicity, no significant changes in routine haematology or hepatic enzymes, and no organ-specific lesions in standard histopathology. As an endogenous peptide, MOTS-c is unlikely to produce significant immunogenicity at typical research doses, though anti-MOTS-c antibodies have been detected in some chronic-dosing studies. The theoretical safety considerations centre on the AMPK pathway's broad role in cellular energy homeostasis. AMPK activation drives catabolic processes (fatty acid oxidation, autophagy, glucose disposal) while inhibiting anabolic processes (lipogenesis, protein synthesis). Sustained or excessive AMPK activation could theoretically impair growth, anabolic recovery from exercise, or tissue regeneration — though the pre-clinical data have not identified clinically significant adverse effects at research doses. The folate-cycle component of MOTS-c mechanism raises theoretical considerations about methylation and one-carbon metabolism. The folate-cycle competition with methotrexate suggests that MOTS-c could theoretically affect cellular folate handling and downstream methylation reactions, with potential implications for DNA repair, neurotransmitter synthesis, and other folate-dependent processes. The pre-clinical work has not identified clinically significant methylation perturbations at research doses, but human chronic dosing has not been adequately characterised. Mild injection-site reactions are documented at higher doses. No serious adverse events have been reported in any published MOTS-c research. The acute safety profile in research animals is favourable; chronic and human safety remains incompletely characterised. Research protocols should consider that MOTS-c is an endogenous peptide whose plasma concentration declines with age and metabolic disease — administration is essentially restoring an endogenous regulator rather than introducing a novel pharmacological agent, which is a different safety framing than for synthetic non-endogenous compounds.

UK regulatory status

MOTS-c is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Supply or administration of MOTS-c to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. Research-grade material for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. MOTS-c is not currently on the WADA Prohibited List as a specifically-named substance. However, WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and S0 category (Non-Approved Substances) could be argued to apply depending on WADA interpretation. The exercise-performance research relevance of MOTS-c — improved treadmill endurance and physical activity in aged mice — makes it a substance athletes should treat conservatively pending clearer WADA guidance. Athletes should consult the current annual WADA Prohibited List and seek guidance from their national anti-doping body before any administration. For animal research under ASPA, MOTS-c work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

Frequently asked questions